 incidence lymphoproliferative disorder immunosuppression monoclonal antibody cardiac-transplant recipients BACKGROUND sudden increase incidence post-transplantation lymphoproliferative disorder patients cardiac-transplantation program introduction immunosuppressive drug monoclonal antibody recent years prevent rejection cardiac transplantation METHODS order variables development post-transplantation lymphoproliferative disorder series consecutive cardiac-transplant recipients single institution Univariate analyses multivariate analysis logistic regression RESULTS patients post-transplantation lymphoproliferative disorder percent patients drug percent incidence patients ninefold odds ratio percent confidence interval analysis factor development post-transplantation lymphoproliferative disorder use significant increase risk doses apparent patients cumulative dose mg percent post-transplantation lymphoproliferative disorder patients mg disorder percent CONCLUSION addition immunosuppressive regimen incidence post-transplantation lymphoproliferative disorder cardiac transplantation risk increases cumulative doses risks benefits prophylactic administration light findings value prophylactic immunotherapy cardiac-transplant recipients